Abstract: The present invention relates to the technical field of medicines, and provides a fused ring compound, a pharmaceutical composition containing the same, and use of the fused ring compound. The compound has a structure as shown in formula (I), or a tautomer, a mesomer, a racemat, an enantiomer, a diastereoisomer or a mixture thereof, a metabolite, a metabolic precursor, an isotope substitution form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a cocrystal thereof. The compound provided by the present invention can be used for treating cancers caused by KRAS mutation. The cancers caused by KRAS mutation are selected from one or more cancers caused by KRAS G12C, KRAS G12V, KRAS G12A and G12D mutations. In particular, the compound can serve as a G12D inhibitor and has relatively high inhibitory activity.

Abstract: The present invention discloses a compound as a sodium channel regulator, and this type of compound can effectively inhibit and block the activity of Nav1.8 ion channel, a subtype of voltage-gated sodium channels, and can be used as a specific Nav1.8 inhibitor and to prepare drugs for the treatment of pain diseases mediated by Nav1.8 such as of intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, primary pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, and cardiac arrhythmia, with broad application prospects.

Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.

Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.

Abstract: According to an example, to access a network through a Layer 2 Tunnel Protocol (L2TP) includes assigning a private network IP address to a public network user device, and transmitting a route of a surveillance segment to the public network user device, such that, after the route of the surveillance segment is received by the public network user device, an IP address of the L2TP virtual interface of the public network user device is configured as a next-hop of the route. When an access request to a surveillance device in the private network is initiated, a routing table of the public network user device is searched to find a matching route of the surveillance segment according to an IP address of the surveillance device. The access request is transmitted to an L2TP server through the L2TP virtual interface, and forwarded to the surveillance device.

Abstract: According to an example, to access a surveillance network through a Layer 2 Tunnel Protocol (L2TP) includes a private network IP address is assigned to a public network user device, and a route of a surveillance segment is transmitted to the public network user device, such that, after the route of the surveillance segment is received by the public network user device, an IP address of the L2TP virtual interface of the public network user device is configured as a next-hop of the route. When an access request to a surveillance device in the private network is initiated, a routing table of the public network user device is searched to find a matching route of the surveillance segment according to an IP address of the surveillance device. The access request is transmitted to an L2TP server through the L2TP virtual interface, and forwarded to the surveillance device.